GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Headquartered in Dublin, Ireland, the company's primary focus is on the development of proprietary mebufotenin (5-MeO-DMT) therapies. Its lead product candidate, GH001, is an inhalable formulation of mebufotenin currently advancing through clinical trials for treatment-resistant depression (TRD), with plans to initiate global Phase 3 trials. The company is also developing GH002, an intravenous formulation, and GH003, an intranasal formulation, both in preclinical stages. As a clinical-stage company, GH Research does not currently generate product revenue and relies on funding from equity offerings and investors to support its research and development activities. Its competitive position lies in its specialized focus on fast-acting, psychedelic-inspired compounds administered in supervised medical settings, aiming to provide rapid-onset and durable efficacy for patients who have failed prior conventional antidepressant therapies.
